Constipation Treatment Drug Market Scope
Constipation Treatment Drug helps to get instant relief from the constipation problems. This problem is referred to the indigested food which is infrequent or hard to pass through the body. It causes lots of complication such as hemorrhoids, abdominal pain, etc. Treatments for these diseases depends on various factors such as the duration from which a person is suffering from this problem. It is seen that the general population rates of constipation are up to 2 -30 percentage. In which the elderly people living in old age has the rate of constipation up to 50-75 percent.
The market study is being classified by Type (Laxatives, Chloride Channel Activators, 5-HT4 Receptor Agonists, GC-C Agonists and Peripherally Acting Mu-Opioid Receptor Antagonists), by Application (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies) and major geographies with country level break-up.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Constipation Treatment Drug market throughout the predicted period.
AstraZeneca (United Kingdom), Bayer AG (Germany), Sanofi (France), Sucampo Pharmaceuticals, Inc. (United States), Takeda Pharmaceuticals Company Limited (India), Ironwood Pharmaceuticals, Inc. (United States), Bausch Health (Canada), Abbott Laboratories (United States), Cosmo Pharmaceuticals NV (Ireland) and Synergy Pharmaceuticals, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Prestige Brands Holdings, Inc. (United States), Janssen Pharmaceutical Company (Belgium) and Shionogi & Co., Ltd. (Japan).
AdvanceMarketAnalytics has segmented the market of Global Constipation Treatment Drug market by Type, Application and Region.
On the basis of geography, the market of Constipation Treatment Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diseases Type, the sub-segment i.e. Chronic idiopathic constipation (CIC) will boost the Constipation Treatment Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of administration, the sub-segment i.e. Oral will boost the Constipation Treatment Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
On 29th November 2018, EA Pharma Co., Ltd., Eisai Co., Ltd., Mochida Pharmaceutical Co., Ltd. launched a drug for constipation treatment known as MOVICOL. It is the first polyethylene glycol preparation for Chronic Constipation in Japan.
- Industry Players are Making a High Trend by Investing in Development of Novel Specialty Constipation Treatment
- The Pervasiveness of IBS-C, OIC, and Chronic Constipation among People
- Increasing Habits of Eating Junk Food
- Rising Geriatric Population
- Emerging Economies Opening New Opportunities for Market
- Growing Incidences of Functional Constipation across the Globe
- Popularity Of Over the Counter (OTD) Drugs Has Restrains the Market
- Availability of Alternative Substitutes Present Such as Home Remedies
- Low Awareness Regarding Diagnosis and Treatment Methods for Chronic Idiopathic Constipation
Key Target AudienceDrug Manufacturers, Drug Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers and Potential Investors
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase